D-Day
-221 daysScientific program
Venue | Songdo Convensia Grand-Ballroom | |||
---|---|---|---|---|
Date | Nov 26 (Fri) 2021 | |||
Moderator | Shim, Myung-Sun (Hallym University, Korea) | |||
Time table | Topics | Chair / Speaker | ||
16:00-16:10 | Welcome address Kwak, Cheol (President, KUOS, Seoul National University, Korea) | |||
16:10-16:30 | Keynote Lecture Kwak, Cheol (President, KUOS, Seoul National University, Korea) | |||
Biochemical relapse after radical prostatectomy and efficacy of salvage radiotherapy in patients with prostate cancer Ahn, Hanjong(University of Ulsan, Korea) | ||||
16:30-17:30 | Surgery (1) Byun, Seok-Soo(Seoul National University, Korea) Uemura, Hirotsugu (Kindai University, Japan) Takenaka, Atsushi (Tottori University, Japan) |
|||
16:30-16:45 | Robot partial nephrectomy for totally endophytic tumor Seo, Seong Il (Sungkyunkwan University, Korea) | |||
16:45-17:00 | ePLND in very high risk prostate cancer Byun, Seok-Soo (Seoul National University, Korea) | |||
17:00-17:15 | Development and future vision of the Made-in Japan surgical robot system Hinata, Nobuyuki (Hiroshima University, Japan) | |||
17:15-17:30 | Q & A | |||
17:30-18:30 | Prostate Cancer (1) Jeon, Seong Soo (President, Sungkyunkwan University, Korea) Egawa, Shin (Jikei University, Japan) Ou, Yen-Chuan (Tungs’ Taichung MetroHarbor Hospital, Taiwan) |
|||
17:30-17:45 | Expression of PD-L1 in needle biopsy prostate cancer tissue Shim, Kang Hee (Ajou University, Korea) | |||
17:45-18:00 | Evolving landscape of prostate cancer in 2021 Kevin Lu (Taichung Veterans General Hospital, Taiwan) | |||
18:00-18:15 | Penile rehabilitation after radical prostatectomy Lee, Sung Won (Sungkyunkwan University, Korea) | |||
18:15-18:30 | Q & A | |||
18:30 | Adjourn |
Venue | Songdo Convensia Grand-Ballroom | |
---|---|---|
Date | Nov 27 (Sat) 2021 | |
Moderator | Shim, Myung-Sun (Hallym University, Korea) | |
Time table | Topics | Chair / Speaker |
09:00-09:20 | Introductory RemarksJeon, Seong Soo (President, Sungkyunkwan University, Korea) Nonomura, Norio (Osaka University, Japan) Chiang, Po-Hui (Chang Gung Memorial Hospital, Taiwan) |
|
Congratulatory remarksAhn, Hanjong (University of Ulsan, Korea) | ||
09:20-10:20 | Prostate cancer (2)Kim, Sunil (Ajou University, Korea) Nonomura, Norio (Osaka University, Japan) Shiroki, Ryoichi (Fujita Health University, Japan) |
|
09:20-09:35 | PARP inhibitor in mCRPCKitamura, Hiroshi (Toyama University, Japan) | |
09:35-09:50 | Germline genetic variants in prostate cancer patients in JapanTerada, Naoki (Miyazaki University, Japan) | |
09:50-10:05 | Current status and challenges of PSA screening in Korea Ko, Young Hwii (Yeungnam University, Korea) | |
10:05-10:20 | Q & A | |
10:20-10:40 | Coffee Break | |
10:40-11:55 | Kidney cancerSong, Cheryn (University of Ulsan, Korea) Kimura, Takahiro (Jikei University, Japan) Pang, ST Jacob (Chang Gung Memorial Hospital, Taiwan) |
|
10:40-10:55 | 1st line IO treatment for mRCC: Real word dataKondo, Tsunenori (Tokyo Women's Medical University, Japan) | |
10:55-11:10 | Current status and future prospect of IO-TKI combined therapy for metastatic renal cell carcinomaMiyake, Hideaki (Hamamatsu University, Japan) | |
11:10-11:25 | Real world therapeutic pattern for recurrent localized kidney cancer in KoreaKim, Sung Han (National Cancer Center, Korea) | |
11:25-11:40 | Pathological node-positive renal cell carcinoma is associated with worse survival outcome: A recall for TMN staging revision.Yu, Kai-Jie(Chang Gung Memorial Hospital, Taiwan) | |
11:40-11:55 | Q & A | |
11:55-13:30 | Lunch | |
13:30-14:45 | Urothelial cancerSeo, Ho Kyung (National Cancer Center, Korea) Nishiyama, Hiroyuki (Tsukuba University, Japan) Chiang, Po-Hui (Chang Gung Memorial Hospital, Taiwan) |
|
13:30-13:45 | Current evidence for systemic treatment for untreated metastatic urothelial carcinomaInokuchi, Junichi (Kyushu University, Japan) | |
13:45-14:00 | The role of Enfortumabvedotin in advanced urothelial carcinoma Park, Inkeun (Gachon University, Korea) | |
14:00-14:15 | Prognostic and Predictive Factors for metastatic urothelial carcinoma patients treated with PembrolizumabKawashima, Atsunari (Osaka University, Japan) | |
14:15-14:30 | Clinical outcome of urachal cancer in Korean patients: multi-institutional studyYu, Young Dong (Cha Medical University, Korea) | |
14:30-14:45 | Neoadjuvant immune check point inhibitors for localized bladder cancer-real world experience sharing.Luo, Hao Lun(Chang Gung Memorial Hospital, Taiwan) | |
14:45-15:10 | Coffee Break | |
15:10-16:25 | Research Yun, Seok Joong (Chungbuk National University, Korea) Chang, Chao-Hsiang (China Medical University, Taiwan) |
|
15:10-15:25 | Germline genetic variants in prostate cancer patients in Korea Ha, Hong Koo (Pusan National University, Korea) | |
15:25-15:40 | The gut microbiome and prostate cancerFujita, Kazutoshi (Kindai University, Japan) | |
15:40-15:55 | Development of AI to improve outcomes of TUR-BTIkeda, Atsushi (Tsukuba University, Japan) | |
15:55-16:10 | MiR-26a-5p as a useful therapeutic target for upper tract urothelial carcinoma by regulating WNT5A/B-catenin signalingChung, Yueh Hua (Chang Gung Memorial Hospital, Taiwan) | |
16:10-16:25 | Q & A | |
16:25-17:25 | Surgery (2)Jeong, Byong Chang (Sungkyunkwan University, Korea) Eto, Masatoshi (Kyushu University, Japan) Wu, Wen-Jeng (Kaohsiung Municipal Ta-Tung Hospital, Taiwan) |
|
16:25-16:40 | Technique for Extended PLND and tip for preventing of symptomatic lymphocele during RC in MIBCJang, Won Sik (Yonsei University, Korea) | |
16:40-16:55 | Prostate surgery: Da Vinci SP (single port) radical prostatectomy Kang, Sung-Gu (Korea University, Korea) | |
16:55-17:10 | 12 year experiences of HIFU for the treatment of prostate cancerChiang, Po-Hui (JhongSiao Urological Hospital, Taiwan) | |
17:10-17:25 | Q & A | |
17:25-17:30 | Closing RemarkJeon, Seong Soo (President, Sungkyunkwan University, Korea) |